reductions

Alnylam to Advance Zilebesiran into Global Phase 3 Cardiovascular Outcomes Trial

- Phase 3 Trial Informed by KARDIA-3 Phase 2 Study Results Presented as a Late-Breaking Abstract at the European Society…

3 days ago

Bests Market Segment Report: Record Catastrophe Bond Issuance Boosts ILS Capacity and Reshapes Pricing Landscape

OLDWICK, N.J.--(BUSINESS WIRE)--#insurance--Reinsurance pricing at the midyear 2025 renewals was the most favorable pricing for cedents in recent years, indicating…

1 week ago

Rhythm Pharmaceuticals Presents Data on MC4R Agonists Setmelanotide and Bivamelagon at ENDO 2025

- Presentations highlight clinically meaningful reductions in BMI in patients with acquired hypothalamic obesity – - Full data from Phase…

2 months ago

GMS Reports Fourth Quarter and Fiscal Year 2025 Results

Resilient Pricing Despite Challenging and Uncertain End Market Conditions; Additional Structural Cost Reductions RealizedTUCKER, Ga.--(BUSINESS WIRE)--GMS Inc. (NYSE: GMS), a…

3 months ago

Dupixent (dupilumab) Data at Revolutionizing Atopic Dermatitis (RAD) Conference Reinforce Use in Atopic Dermatitis Patients with Skin of Color

Atopic dermatitis is a chronic disease that disproportionately impacts communities of color Dupixent achieved 75% or greater improvement in overall…

3 months ago